A Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice among Chinese NSCLC Patients

Trial Identifier:	D5160R00026
Sponsor:	AstraZeneca
NCTID::	NCT03485326
Start Date:	April 2020
Primary Completion Date:	August 2023
Study Completion Date:	August 2023
Condition:	Lung Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
China	Beijing, China, 100142
China	Chengde, China
China	Chengdu, China, 610041
China	Dingzhou, China
China	Fuzhou, China
China	Ganzhou, China
China	Guangzhou, China
China	Guangzhou, China, 510010
China	Guangzhou, China, 510120
China	Guangzhou, China, 510080
China	Hangzhou, China
China	Hangzhou, China, 310014
China	Hangzhou, China, 310003
China	Hangzhou, China, 310052
China	Hangzhou, China, 321000
China	Harbin, China, 150081
China	Huanghua, China
China	Jinan, China, 2501117
China	Linhai, China, 317000
China	Nanchang, China
China	Shanghai, China, 200052
China	Shijiazhuang, China, 050035
China	Suzhou, China, 215004
China	Taiyuan, China, 030000
China	Tianjin, China, 300052
China	Weihai, China
China	Wuhan, China, 430079
China	Wuhan, China, 430030
China	Zhuji, China

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company